Lista de obras - Anthony Cerami - Dominio Público Uruguay

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

artículo científico publicado en 2015

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema

artículo científico publicado en 2020

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

artículo científico publicado en 2011

A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.

artículo científico publicado en 2010

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

artículo científico publicado en 2014

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

artículo científico publicado en 2013

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

artículo científico publicado en 2014

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response

artículo científico publicado en 2014

ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability.

artículo científico publicado en 2016

ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.

artículo científico publicado en 2011

Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative

artículo científico publicado en 2006

Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy

artículo científico publicado en 2013

Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis

artículo científico publicado en 2017

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

artículo científico publicado en 2006

Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury.

artículo científico publicado en 2002

Erythropoietin and engineered innate repair activators.

artículo científico publicado en 2013

Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?

artículo científico publicado en 2004

Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor.

artículo científico publicado en 2013

Erythropoietin both protects from and reverses experimental diabetic neuropathy

artículo científico publicado en 2004

Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection

scholarly article

Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury

artículo científico publicado en 2002

Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis

artículo científico publicado en 2003

Erythropoietin therapy for acute stroke is both safe and beneficial

artículo científico publicado en 2002

Erythropoietin: not just about erythropoiesis

artículo científico publicado en 2010

Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin

artículo científico publicado en 2015

Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis

scientific article published on 01 January 2004

Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury.

artículo científico publicado en 2005

Neuroprotective properties of epoetin alfa.

artículo científico publicado en 2002

Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing.

artículo científico publicado en 2009

Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity

scientific article published on 01 April 2006

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

artículo científico publicado en 2003

Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives

artículo científico publicado en 2006

Reply to Abdelwahid and Smith: The effect on cardiomyocytes of helix B-surface peptide (HBSP), a peptide with cell-protective but not erythropoietic activities of erythropoietin.

artículo científico publicado en 2011

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

artículo científico publicado en 2012

Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.

artículo científico publicado en 2013

TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury

artículo científico publicado en 2008

Lista de obras de Anthony Cerami

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response

ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability.

ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.

Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative

Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy

Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury.

Erythropoietin and engineered innate repair activators.

Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?

Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor.

Erythropoietin both protects from and reverses experimental diabetic neuropathy

Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection

Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury

Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis

Erythropoietin therapy for acute stroke is both safe and beneficial

Erythropoietin: not just about erythropoiesis

Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin

Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis

Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury.

Neuroprotective properties of epoetin alfa.

Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing.

Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives

Reply to Abdelwahid and Smith: The effect on cardiomyocytes of helix B-surface peptide (HBSP), a peptide with cell-protective but not erythropoietic activities of erythropoietin.

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.

TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury